Amgen acquisition of Five Prime Therapeutics : Amgen has agreed to acquire Five Prime Therapeutics, a clinical-stage biotech company, for about $1.9 billion, to add a phase 3 ready gastric cancer candidate called bemarituzumab. Based in California, Five Prime Therapeutics is engaged in developing immuno-oncology and targeted cancer therapies. Amgen will acquire the biotech company […]
California-based Five Prime Therapeutics and Chinese biopharma Zai Lab have initiated a pivotal Phase 3 trial of bemarituzumab (FPA144) in combination with chemotherapy for patients with advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. The trial, named FIGHT, represents a significant milestone in the development of targeted therapies for these challenging cancers. The FIGHT […]